Significance of Multiple Lymphocyte-to-C-Reactive Protein Ratios in Predicting Long-Term Major Cardiovascular Adverse Events in Emergency Percutaneous Coronary Intervention Patients with ST-Segment Elevation Myocardial Infarction

References

• Vaduganathan M, Mensah GA, Turco JV, et al. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361–2371. doi:10.1016/j.jacc.2022.11.005
   PubMed Web of Science ®Google Scholar
• Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nature Med. 2011;17(11):1410–1422. doi:10.1038/nm.2538
   PubMed Web of Science ®Google Scholar
• Joseph P, Leong D, Mckee M, et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ Res. 2017;121(6):677–694. doi:10.1161/circresaha.117.308903
   PubMed Web of Science ®Google Scholar
• Vogel B, Claessen BE, Arnold SV, et al. ST-segment elevation myocardial infarction. Nature Reviews Disease Primers. 2019;5(1):39. doi:10.1038/s41572-019-0090-3
   PubMedGoogle Scholar
• Özcan C, Deleskog A, Schjerning Olsen AM, et al. Coronary artery disease severity and long-term cardiovascular risk in patients with myocardial infarction: a Danish nationwide register-based cohort study. Eur Heart J Cardiovasc Pharmacother. 2018;4(1):25–35. doi:10.1093/ehjcvp/pvx009
   PubMed Web of Science ®Google Scholar
• Mcmanus DD, Gore J, Yarzebski J, et al. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am j Med. 2011;124(1):40–47. doi:10.1016/j.amjmed.2010.07.023
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. New Engl J Med. 2005;352(16):1685–1695. doi:10.1056/NEJMra043430
   PubMed Web of Science ®Google Scholar
• Moreira DM, Da Silva RL, Vieira JL, et al. Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease. Am J Cardiovas Drugs. 2015;15(1):1–11. doi:10.1007/s40256-014-0094-z
   PubMed Web of Science ®Google Scholar
• Swirski FK, Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and disease. Nat Rev Immunol. 2018;18(12):733–744. doi:10.1038/s41577-018-0065-8
   PubMed Web of Science ®Google Scholar
• Zhao J, Lv H, Yin D, et al. Systemic immune-inflammation index predicts long-term outcomes in patients with three-vessel coronary disease after revascularization: results from a large cohort of 3561 patients. J Inflamm Res. 2022;15:5283–5292. doi:10.2147/jir.s385990
   PubMed Web of Science ®Google Scholar
• Arroyo-Espliguero R, Avanzas P, Cosín-Sales J, et al. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J. 2004;25(5):401–408. doi:10.1016/j.ehj.2003.12.017
   PubMed Web of Science ®Google Scholar
• Fordjour PA, Wang Y, Shi Y, et al. Possible mechanisms of C-reactive protein mediated acute myocardial infarction. Eur J Pharmacol. 2015;760:72–80. doi:10.1016/j.ejphar.2015.04.010
   PubMed Web of Science ®Google Scholar
• Yao WY, Wu XS, Liu SL, et al. Preoperative lymphocyte to C-reactive protein ratio as a new prognostic indicator in patients with resectable gallbladder cancer. Hepatobi Pancreat Dis Internat. 2022;21(3):267–272. doi:10.1016/j.hbpd.2021.08.006
   PubMed Web of Science ®Google Scholar
• Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer. Ann Surg. 2020;272(2):342–351. doi:10.1097/sla.0000000000003239
   PubMed Web of Science ®Google Scholar
• Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer. Clin Nutr. 2020;39(4):1209–1217. doi:10.1016/j.clnu.2019.05.009
   PubMed Web of Science ®Google Scholar
• Liu Y, Ye T, Chen L, et al. Preoperative lymphocyte to C-reactive protein ratio: a new prognostic indicator of post-primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Int Immunopharmacol. 2023;114:109594. doi:10.1016/j.intimp.2022.109594
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138(20):e618–e51. doi:10.1161/cir.0000000000000617
   PubMed Web of Science ®Google Scholar
• Ryan TJ, Bauman WB, Kennedy JW, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American Heart Association/American college of cardiology task force on assessment of diagnostic and therapeutic cardiovascular procedures (committee on percutaneous transluminal coronary angioplasty). Circulation. 1993;88(6):2987–3007. doi:10.1161/01.cir.88.6.2987
   PubMed Web of Science ®Google Scholar
• Liu Y, Ye T, Chen L, et al. Systemic immune-inflammation index predicts the severity of coronary stenosis in patients with coronary heart disease. Coronary Artery Disease. 2021;32(8):715–720. doi:10.1097/mca.0000000000001037
   PubMed Web of Science ®Google Scholar
• Verheggen PW, De Maat MP, Cats VM, et al. Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. Eur Heart J. 1999;20(8):567–574. doi:10.1053/euhj.1998.1312
   PubMed Web of Science ®Google Scholar
• Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54(4):281–292. doi:10.1016/j.jacc.2009.03.054
   PubMed Web of Science ®Google Scholar
• Ozcan Cetin EH, Cetin MS, Aras D, et al. Platelet to lymphocyte ratio as a prognostic marker of in-hospital and long-term major adverse cardiovascular events in st-segment elevation myocardial infarction. Angiology. 2016;67(4):336–345. doi:10.1177/0003319715591751
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu J, Liu L, et al. Association of systemic inflammatory response index and pan-immune-inflammation-value with long-term adverse cardiovascular events in ST-segment elevation myocardial infarction patients after primary percutaneous coronary intervention. J Inflamm Res. 2023;16:3437–3454. doi:10.2147/jir.s421491
   PubMed Web of Science ®Google Scholar
• Di Fusco SA, Arca M, Scicchitano P, et al. Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target. Heart. 2022;109(1):18–25. doi:10.1136/heartjnl-2021-320708
   PubMed Web of Science ®Google Scholar
• Xu B, Chen K, Su W, et al. Correlation between GDF11 serum levels, severity of coronary artery lesions, and the prognosis of patients with ST-segment elevation myocardial infarction. J Cardiovasc Translat Res. 2023;16(4):938–947. doi:10.1007/s12265-023-10358-w
   PubMed Web of Science ®Google Scholar
• Chung WY, Seo JB, Choi DH, et al. Immediate multivessel revascularization may increase cardiac death and myocardial infarction in patients with ST-elevation myocardial infarction and multivessel coronary artery disease: data analysis from real world practice. Korean J Inter Med. 2016;31(3):488–500. doi:10.3904/kjim.2014.119
   PubMed Web of Science ®Google Scholar
• Kurtul A, Yarlioglues M, Murat SN, et al. The association of plasma fibrinogen with the extent and complexity of coronary lesions in patients with acute coronary syndrome. Kardiologia Polsk. 2016;74(4):338–345. doi:10.5603/KP.a2015.0196
   PubMed Web of Science ®Google Scholar
• Sharma H, Radhakrishnan A, Nightingale P, et al. Mitral regurgitation following acute myocardial infarction treated by percutaneous coronary intervention-prevalence, risk factors, and predictors of outcome. Am J Cardiol. 2021;157:22–32. doi:10.1016/j.amjcard.2021.07.029
   PubMed Web of Science ®Google Scholar